Endo to provide fill-finish services for Novavax COVID-19 vaccine

By The Science Advisory Board staff writers

September 25, 2020 -- Par Sterile Products has entered a nonexclusive agreement with Novavax to provide fill-finish manufacturing services at its Rochester, MI, plant for Novavax's COVID-19 vaccine candidate.

Under the agreement, Par Sterile, a subsidiary of Endo International, has begun production of the NVX-CoV2373 final drug candidate, with initial batches to be used in Novavax's phase III clinical trial in the U.S. Par Sterile will also fill-finish vaccine intended for commercial distribution in the U.S.

NVX-CoV2373 is currently in multiple phase II clinical trials to evaluate safety and immunogenicity. Interim data is expected before the end of 2020. Novavax has secured $2 billion in funding for its global coronavirus vaccine program, including $388 million from the Coalition for Epidemic Preparedness Innovations (CEPI).

Financial and other terms of the agreement were not disclosed.


Copyright © 2020 scienceboard.net
 


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.